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Abstract
Background: Prior studies reveal that a significant proportion of patients with cystic fibrosis (CF) and advanced lung
disease are not referred for lung transplant (LTx) evaluation. We sought to assess expert CF physician perspectives on
the timing of LTx referral and investigate their LTx knowledge.
Methods: We developed an online anonymous survey that was distributed by the Cystic Fibrosis Foundation (CFF) to
the medical directors of all CFF-accredited care centers in the United States in 2015. The survey addressed only adult
patients (≥18 years old) and was sent to 119 adult CF physicians, 86 CFF-affiliated CF physicians (who see adults and
children, but have smaller program sizes than adult or pediatric centers), and 127 pediatric CF physicians (who see
some adults, but mostly children). The focus of the questions was on CFF-care center characteristics, physician experience
and indications/contraindications to referral for LTx evaluation.
Results: There were 114/332 (34%) total responses to the survey. The response rates were: 57/119 (48%) adult physicians,
12/86 (14%) affiliate physicians and 43/127 (34%) pediatric physicians; 2 physicians did not include their CFF center type.
Despite the poor ability of FEV1 < 30% to predict death within 2 years, 94% of responding CF physicians said they would
refer an adult patient for LTx evaluation if the patient’s lung function fell to FEV1 < 30% predicted. Only 54% of
respondents report that pulmonary hypertension would trigger referral. Pulmonary hypertension is an
internationally recommended indication to list a patient for LTx (not just for referral for evaluation). Very few
physicians (N = 17, 15%) employed components of the lung allocation score (LAS) to determine the timing of
referral for LTx evaluation. Interestingly, patient preference not to undergo LTx was “often” or “always” the
primary patient-related reason to defer referral for LTx evaluation for 41% (47/114) of respondents.
Conclusions: Some potential barriers to timely LTx referral for patients with CF include physician knowledge
regarding non-lung function-based recommendations related to timing of referral and listing for LTx, and patient
preference not to undergo LTx. Further exploration of physician-level and CF patient-level barriers to timely LTx
referral is warranted.
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Background
Cystic fibrosis (CF) is a progressive, lethal genetic disease
that affects an estimated one in 3500 newborns in the
United States (US) [1]. Approximately 81–84% of patients
diagnosed with CF are treated at Cystic Fibrosis Founda-
tion (CFF)-accredited Programs nationwide, where expert
care and specialized disease management is evidence-
based via care guidelines [1, 2]. Physicians who work at
CFF-accredited centers are internists or pediatricians
often with subspecialty pulmonary medicine training. The
CFF has a mission “to find a cure for CF and improve the
quality of life for people with the disease” [1].
Despite therapeutic advances and increasing life expect-
ancy, respiratory failure remains the most frequent cause
of premature death among patients with CF [1, 3]. Lung
transplantation (LTx) is a treatment option for select pa-
tients with CF and advanced lung disease. The decision to
pursue organ transplantation is a complex balance of pa-
tient preference and physician judgment of medical indi-
cation and patient candidacy. However, we have yet to
fully understand the factors leading to referral for lung
transplantation. Notably, a study of patients in the CFF
Patient Registry demonstrated that only 65% of patients
who decidedly met medical criteria (forced expiratory vol-
ume in one second (FEV1) <30% predicted for two con-
secutive years) were referred for LTx evaluation [4].
Among patients with FEV1 < 30% predicted, more US CF
patients die without LTx each year after reaching this
threshold than undergo transplantation [5]. Disparities in
access to LTx referral based on socioeconomic status have
been highlighted, but it remains unclear whether physician
or patient factors led to non-referral of these patients with
CF and advanced lung disease [4]. A retrospective analysis
of 256 deaths among patients with CF in France, 2007–
2010, revealed that half of the deaths (n = 129) occurred in
patients who did not undergo LTx [6]. Among the patients
who died without listing for LTx despite having an indica-
tion for transplant, LTx was never considered by their care
team in 39% of patients; in cases where transplant had
been considered, 25% of patients who died without listing
had refused LTx [6]. No studies to date have examined
physicians’ knowledge, attitudes and behaviors surround-
ing referral of patients with CF for LTx evaluation. Thus,
the objective of the current study was to elucidate poten-
tial barriers to referral of patients with CF for LTx evalu-
ation through investigation of the perspectives of expert
CF physicians in the US. We hypothesized that the study
would reveal patterns of referral/non-referral and identify
potential targets for intervention to improve access to LTx
among patients with CF.
Methods
The study protocol was reviewed by the Institutional Re-
view Board at the University of Washington and was
determined to afford Minimal Risk to subjects (physicians)
(IRB #48957). A waiver of written informed consent was
obtained; subjects were consented in the email introdu-
cing the survey and provided implicit consent when they
followed the email link to the online survey.
Data collection and study population
A 15-question investigator-designed online anonymous
survey was created focused on referral of adults (≥18 years)
with CF for LTx evaluation. The questions addressed
CFF-care center characteristics, physician experience,
indications/contraindications to referral for LTx evalu-
ation, and opinions regarding the benefit of LTx in pa-
tients with CF (see Additional file 1 for survey items). The
online survey was piloted with physicians who care for
patients with CF at the University of Washington for
feasibility. Pilot respondents found that the 15-question
survey took fewer than 10 min to complete and was
easily understood; pilot responses were not included in
the final data analysis. The survey was formatted in
SurveyMonkey® and subsequently distributed via email
by the CFF to the center directors, program directors
and affiliate directors of all CFF-accredited care centers
in the US. Each CFF-care center received one survey for
each of its program types (Adult, Affiliate, and Pediatric).
As both Affiliate and Pediatric CF programs follow
pediatric and adult patients albeit in varied proportions,
they were included in the study to complete questions
focused only on their adult patients. Surveys were com-
pleted between January 28, 2015 and February 20, 2015.
Results were provided to the University of Washington
investigators in an anonymous aggregated dataset, and
were analyzed using STATA 13.1 (StataCorp LP, College
Station, Texas).
Statistical analyses
Descriptive statistics were used to describe the CFF-care
center characteristics, physicians, and responses to lung
transplant-related questions. The data was stratified by pro-
gram type (Adult, Affiliate, Pediatric), CF physician experi-
ence (post-hoc dichotomization: <15 years versus ≥ 15 years),
and distance from LTx center (direct affiliation [0 min
distance] versus not directly affiliated [<30/30–75/75–
150/>150 min driving distance]), and further analysis
was performed on these subgroups.
The size of a CF center was estimated based on the
number of adult CF patients cared for each year (entered
as a “free text” number) and then categorized a priori
into four groups (group1: <50 patients, group 2: 50–99
patients, group 3: 100–199 patients, group 4: ≥200 patients).
The number of adult CF patients referred annually for lung
transplant evaluation was also entered as a “free text”
number; if a respondent provided a range (e.g. 0–5), then
the mid-point of the range was used (rounded up to the
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nearest whole number) as the actual number referred per
year. The percentage of adult CF patients referred annu-
ally was then calculated by dividing the number of pa-
tients referred by the absolute number of adult patients
cared for each year. Respondents were asked to report the
United Network for Organ Sharing (UNOS) region for
their program and the proportion of respondents in each
UNOS region was compared to the proportion of all
CFF-accredited programs in each UNOS region in
order to assess for a geographic response bias.
Chi-square analysis was used to evaluate for differences
by program type (Adult, Affiliate, Pediatric) in distance
from lung transplant center, years in independent CF
practice, Lung Allocation Score (LAS) use, and patient-
related reasons to defer referral for LTx evaluation. Multi-
nomial (polytomous) regression was used to model differ-
ences in: model 1–program size and proportion of adult
patients referred per year; model 2–indications that would
trigger referral for LTx evaluation; model 3–colonization
with specific organisms that would prevent referral for
LTx evaluation; model 4–comorbidities that would pre-
vent referral for LTx evaluation.
Results
The survey was sent to 127 Pediatric Programs, 119 Adult
Programs, and 86 CFF-Affiliated Programs. There were
114/332 (34%) total responses to the survey (Table 1). The
response rates differed by Program type: 57/119 (48%)
Adult Programs, 12/86 (14%) Affiliate Programs and 43/
127 (34%) Pediatric Programs. Two respondents did not
report their Program type. The number of years of in-
dependent practice of CF did not vary among Program
types (p = 0.083); however, with dichotomization of CF
physician experience (< or ≥15 years), Adult Programs
have fewer respondents with ≥ 15 years of experience
(p = 0.008). Respondents were evenly geographically
distributed across the 11 UNOS transplant regions
(Additional file 1: Figure S1). Respondents from Adult
Programs were more likely to be directly affiliated with
a lung transplant center than respondents from Affiliate
or Pediatric Programs (p = 0.009) (Table 1); the distance
from a lung transplant center was significantly different
between Program types (p = 0.014). Adult Programs were
larger than Affiliate and Pediatric Programs (p < 0.001),
but there was no significant difference in the percentage
of adult patients referred for LTx evaluation each year
(multinomial regression data shown in Additional file 1).
Of the respondents, 107 (94%) stated that they would
refer an adult patient for LTx evaluation if the patient’s
lung function reached FEV1 < 30% predicted, 90 (79%)
respondents would refer in the setting of a rapid decline
in FEV1 and 110 (96%) respondents use at least one of
those FEV1 criteria as a trigger for referral. Only approxi-
mately half (62/114, 54%) would refer a patient with a









Program size, n (%)b
< 50 adult patients 38 (33%) 4 (7%) 11 (92%) 22 (51%)
50–99 adult patients 31 (27%) 18 (32%) 0 13 (30%)
100–199 adult patients 27 (24%) 21 (37%) 1 (8%) 5 (12%)
≥ 200 adult patients 17 (15%) 13 (23%) 0 3 (7%)
Percent referred/yearc, Median (IQR) 3.5% (2.0%–6.4%) 3.2% (2.5%–5.8%) 5.0% (3.3%–7.5%) 3.3% (0–10.0%)
Distance to lung transplant center, n (%)
Direct affiliation 39 (34%) 27 (47%) 2 (17%) 9 (21%)
< 30 min 16 (14%) 6 (11%) 1 (8%) 9 (21%)
30–75 min 18 (16%) 10 (18%) 0 8 (19%)
75–150 min 16 (14%) 7 (12%) 3 (25%) 5 (12%)
> 150 min 25 (22%) 7 (12%) 6 (50%) 12 (28%)
Years independently practicing CF medicine, n (%)
< 5 years 13 (11%) 9 (16%) 0 3 (7%)
5 to < 10 years 19 (17%) 13 (23%) 2 (17%) 4 (9%)
10 to < 15 years 21 (18%) 12 (21%) 1 (8%) 7 (16%)
≥ 15 years 61 (54%) 23 (40%) 9 (75%) 29 (67%)
IQR interquartile range, CF cystic fibrosis
aTwo respondents did not report Program type
bOne adult Program did not report size of the Program
cCalculated by division of number of referrals by total number of adult patients followed by program(s)
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diagnosis of pulmonary hypertension (Table 2). Based on
multinomial regression, respondents from a Pediatric
Program were more likely than Adult Program respon-
dents to choose a rapid decline in FEV1 as a trigger for
LTx referral (p = 0.040). Other potential indications
were not statistically different between Program types
(Additional file 1: Table S1). Only 17/114 (15%) respon-
dents reported considering the LAS prior to referral of
patients, and rates of use were not significantly differ-
ent between Program types (p = 0.125). In relation to
patient outcomes, 100 (88%) and 103 (90%) respondents
reported that LTx improves survival and quality of life,
respectively, for patients with CF who undergo the
procedure.
Physicians were asked about potential contraindications
that would prevent referral to a LTx center. The questions
were grouped into three categories: colonization with
specific organisms; co-morbidities; and patient-related
factors. For these, 78 (68%) respondents indicated that
colonization with a specific organism (Burkholderia
cenocepacia for a majority of respondents) would pre-
vent referral for LTx evaluation (Table 3). Based on
multinomial regression, respondents from a Pediatric
Program were less likely than Adult Program respon-
dents to choose B. cenocepacia as a potential contra-
indication that would prevent LTx referral (p = 0.005)
(Additional file 1: Table S2), which may be related to a
decreased prevalence of B. cenocepacia in the Pediatric
Programs [7]. With regards to co-morbidities prevent-
ing referral for LTx, 102 (89%) responded, and the most
frequent ones were tissue diagnosis of cancer, end-stage
renal disease (ESRD) requiring dialysis and inadequate
nutritional status (e.g. body mass index, BMI <18) (Table 4).
Based on multinomial regression, respondents from a
Pediatric Program were less likely than Adult Program
respondents to choose end-stage liver disease (ESLD)
(p = 0.038), ESRD (p = 0.031), and depression (p = 0.032)
as potential contraindications that would prevent LTx re-
ferral (Additional file 1: Table S3). Patient preference not
to undergo LTx was “often” or “always” the primary
patient-related reason to defer referral for LTx evaluation
for 47/114 (41%) of respondents (Fig. 1) and was consist-
ent across Program types (p = 0.837). Patient financial or
insurance issues were “rarely” or “never” the primary
patient-related reason to defer referral for LTx evaluation
for a majority of respondents (Fig. 2). Chi-square analysis
revealed that patient financial issues were more frequently
the primary patient-related reason to defer referral for LTx
evaluation among Adult Program respondents (p = 0.048).
The free text “other” option was utilized by 15/114
(13%) of respondents to describe patient-related issues
that would prevent referral. The “other” patient-related
responses included: patient refusal/preference, non-adherence,
tobacco/drug use, nutritional status, and financial issues.
Analyses were also performed on the subgroups defined
by distance from LTx center and CF physician experience
to identify associations with Program types, and causes of
deferred LTx evaluation and detailed results can be
found in the supplemental materials (Additional file 1:
Tables S4–S9).
Discussion
Our national survey of CF physicians in the US herein
identified a number of associations and explanations for
deferred referral of patients with CF for LTx evaluation
that merit further study. Nearly all physicians who
responded to our survey reported that they use the FEV1
(either <30% or a rapid decline) as a trigger for referral
for LTx evaluation. It is clear that these expert CF physi-
cians recognize the lung function criteria for LTx









n (%) n (%) n (%) n (%)
FEV1 < 30% predicted 107 (94%) 53 (93%) 12 (100%) 40 (93%)
NPPV for hypercapnia 96 (84%) 51 (90%) 11 (92%) 33 (77%)
Rapid decline in FEV1 90 (79%) 40 (70%) 10 (83%) 38 (88%)
Hemoptysis not controlled by embolization 75 (66%) 35 (61%) 9 (75%) 29 (67%)
Supplemental oxygen 64 (56%) 29 (51%) 9 (75%) 26 (61%)
Pulmonary hypertension 62 (54%) 34 (60%) 9 (75%) 19 (44%)
Increasing frequency pulmonary exacerbations 57 (50%) 25 (44%) 7 (58%) 24 (56%)
Refractory/recurrent pneumothorax 53 (47%) 26 (46%) 9 (75%) 18 (42%)
Pulmonary exacerbation with ICU admission 38 (33%) 16 (28%) 4 (33%) 18 (42%)
Skipped questionb 2 (2%) 1 (2%) 0 1 (2%)
FEV1 Forced expiratory volume in 1 s, NPPV Noninvasive Positive Pressure Ventilation, ICU intensive care unit
aTwo respondents did not report Program type
bAssumption: none of these would trigger referral for lung transplant evaluation
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referral. Observational data suggests that survival among
patients with CF and FEV1 < 30% is improving over time
[8–10], and a national cohort study of patients in the US
CFF Patient Registry, 2003–2013, demonstrated a median
transplant-free survival of 6.6 years after FEV1 < 30%.
With this observation of increasing survival in patients
with CF and severe lung disease (FEV1 < 30%), we believe
that this may explain recent findings of low referral rates
among patients with CF and FEV1 < 30% in the CFF Pa-
tient Registry [4, 5] regardless of current International
Society for Heart and Lung Transplantation (ISHLT)
guidelines [11].
The timing of referral for LTx evaluation is an aspect
of the “art” of caring for patients with CF, as individual-
ized survival estimates are challenging. Our study thus
highlights important practices among expert CF physi-
cians. The annual median percentage of adult patients at
each center referred for LTx evaluation was 3.5% and
this varied little in subgroup analyses of Program type,
distance from LTx center and CF physician experience.
Nearly all respondents report that FEV1 < 30% predicted
would trigger a referral for LTx evaluation, but the pro-
portion of CF physicians that consider supplemental
oxygen use, pulmonary hypertension, or the frequency/
severity of pulmonary exacerbations is much lower. All
of the indications listed in Table 2 are within the ISHLT
guidelines for referral for LTx evaluation for patients
with CF, and certain ones are indications to list for LTx
(not just indications for referral) [11]. Additionally, very
few respondents report considering the LAS prior to re-
ferral for LTx evaluation; the LAS was adopted in May
2005 in the US in an attempt to maximize net benefit of
transplant by integrating a patient’s waitlist urgency and
1-year post-transplant survival [12]. The LAS is also









n (%) n (%) n (%) n (%)
Burkholderia cenocepacia 63 (55%) 37 (65%) 7 (58%) 17 (40%)
Mycobacterium abscessus 25 (22%) 10 (18%) 4 (33%) 11 (26%)
Burkholderia cepacia complex 24 (21%) 15 (26%) 2 (17%) 7 (16%)
Mycobacterium avium complex (MAC) 6 (5%) 3 (5%) 0 3 (7%)
Multidrug resistant bacteriab 3 (3%) 1 (2%) 0 2 (5%)
Aspergillus fumigatus 1 (1%) 1 (2%) 0 0
Skipped questionc 36 (32%) 16 (28%) 3 (25%) 17 (40%)
aTwo respondents did not report Program type
bMultidrug resistant bacteria, including: Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans
cAssumption: none of these would prevent referral for lung transplant evaluation









n (%) n (%) n (%) n (%)
Tissue diagnosis of cancer 74 (65%) 39 (68%) 9 (75%) 26 (61%)
CF-related ESRD requiring dialysis 50 (44%) 23 (40%) 6 (50%) 21 (49%)
Inadequate nutritional status (e.g. BMI <18) 33 (29%) 18 (32%) 4 (33%) 9 (21%)
CF-related liver cirrhosis 18 (16%) 13 (23%) 0 5 (12%)
CF-related diabetes, poorly controlled 18 (16%) 11 (19%) 2 (17%) 5 (12%)
Depression, anxiety 10 (9%) 3 (5%) 1 (8%) 6 (14%)
Pulmonary hypertension 1 (1%) 0 1 (8%) 0
Osteoporosis 1 (1%) 1 (2%) 0 0
CF-related sinus disease, extensive 0 0 0 0
Gastro-esophageal reflux disease 0 0 0 0
Other (free text response) 31 (27%) 19 (33%) 3 (25%) 9 (21%)
Skipped questionb 12 (11%) 5 (9%) 0 7 (16%)
CF cystic fibrosis, ESRD end-stage renal disease, BMI body mass index
aTwo respondents did not report Program type
bAssumption: none of these would prevent referral for lung transplant evaluation
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utilized for LTx allocation in Germany as of December
2011 [13]. Knowing the components of the LAS that
lead to a higher score (e.g. supplemental oxygen require-
ment, decreased 6-min walk distance, elevated pulmon-
ary artery pressure) could inform a referring physician’s
decision about the timing of referral in the US. Higher
LAS scores are associated with worsened survival among
patients with CF [14, 15] and the LAS incorporates some
of the criteria in the ISHLT guidelines for listing for lung
transplantation–elements that are relevant even in coun-
tries that do not utilize the LAS. It is possible that CF
physicians are focused on lung function parameters in
the guidelines (e.g. FEV1 < 30% predicted) instead of
other important factors considered in the LTx listing
process (e.g. components of the LAS, or frequency/
severity of pulmonary exacerbations). This focus on lung
function may be related to a lack of data about other pa-
rameters (screening for pulmonary hypertension is not
within the CFF guidelines; 6-min walk tests are not rou-
tinely recommended), but focusing only on lung function
could lead to missed opportunities for referral and pro-
vides an opportunity for education about current LTx
practices. Alternatively, CF physicians may have adjusted
their referral practices (at least with respect to lung func-
tion parameters) as their clinical experience has revealed
patients do not seem ready for a LTx evaluation despite
meeting current lung function guidelines for referral.
Unfortunately, many patients with FEV1 < 30% die with-
out LTx, and increasing referral within this population
is critical [5, 6].
Additionally, we observed that a majority of respondents
identified Burkholderia cenocepacia as a contraindication
to LTx referral. Multiple studies, including a recent study
of Canadian patients with CF, have demonstrated that sur-
vival is significantly shortened in patients infected with B.
cenocepacia who undergo LTx [16–19]. Most LTx centers
Fig. 1 Proportion of physicians indicating primary patient-related reason to defer transplant referral is patient preference, by Program type. Panels show
proportion of survey respondents who indicated primary patient-related reason to defer transplant referral is patient preference, by Program type: Adult
Program (top left), Affiliate Program (top right), Pediatric Program (bottom left), All Respondents (bottom right)
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in the US consider B. cenocepacia to be an absolute
contraindication to LTx. Furthermore, in regard to comor-
bidities, respondents who were directly affiliated with a
LTx center were more likely to identify ESLD as a reason
to defer referral, which may be based on the experience
that liver-lung transplantation is exceedingly rare because
of the complexity of the combined surgeries. Respondents
directly affiliated with a LTx center were also more likely
to identify inadequate nutritional status as a reason to
defer referral, which may be based on the experience that
LTx programs often ask the primary CF center to optimize
nutritional status prior to referral. However, it is important
to note that many comorbidities are relative contraindica-
tions and early referral may allow specialists at LTx cen-
ters to intervene on modifiable comorbidities. Finally, CF
physicians’ perceptions of the most frequent patient-
related reasons to defer referral included “patient prefer-
ence not to undergo lung transplantation” and patient
non-adherence. This raises the question of whether pa-
tients understand the risks and benefits of LTx prior to
referral and the consequences of their decision to defer
referral.
Our study has important limitations to consider. As
our overall response rate was low, and at differential
rates between programs, selection bias may have occurred.
However, we had a nearly 50% response rate amongst CF
physicians from Adult Programs who care for the majority
of our study population of interest. Most recipients of LTx
in CF are over 30 years old [20]. Respondents from the
Affiliate and Pediatric programs care for fewer adult pa-
tients with CF, and this may have impacted their survey
responses. The response bias may have been directed
towards those with greater experience and knowledge
in CF and transplant care and thus variability of responses
observed in the study may have been attenuated relative to
the CF care community at large. A number of statistical
Fig. 2 Proportion of physicians who indicated patient-related reasons to defer transplant referral. Panels show proportion of survey respondents
who identified the following patient-related reasons to defer lung transplant referral: patient insurance (top left), patient financial issues (top right),
patient social issues (bottom left), and patient adherence (bottom right)
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analyses were conducted of the survey data leading to a po-
tential concern about multiple testing. We used multinomial
regression to reduce this concern, but false positive statis-
tical associations are possible. Although our study was con-
ducted in the US, CF care in the US aims to adhere to
evidence-based standards and the LTx referral guidelines are
international recommendations, and thus our survey may
have generalizability to the CF global community. Addition-
ally, though a responder bias cannot be excluded, within the
US, we did not identify any significant regional differences
in response rates. Despite the limitations, this was the first
large multicenter survey study to examine the attitudes, be-
haviors, and LTx referral patterns of CF physicians to inform
future studies in this important area of care.
Conclusions
The decision to pursue lung transplantation is a complex
balance of patient preference and physician judgment of
medical indication and patient candidacy. Our study indi-
cates that barriers to referral may be related to patient pref-
erences, clinical characteristics, or physician knowledge
regarding non-lung function-based recommendations re-
lated to the timing of referral and listing for LTx. Interven-
tions to educate CF physicians (both adult and pediatric
patient providers) about the non-lung function-based fac-
tors that impact listing for LTx should be studied and im-
plemented. Further exploration of physician-level and CF
patient-level barriers to timely LTx referral is warranted.
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